Asterias Biotherapeutics (AST) Reports In-Line Q4 EPS

Asterias Biotherapeutics (NYSE: AST) reported Q4 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $608 thousand versus the consensus estimate of $1.07 million.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• JPMorgan cuts 2026 box office forecast on slow third quarter
• Occidental Petroleum releases Q2 2026 earnings considerations